Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 892-897

  Halvorsen, Ole Johan ^a   Rostad, Kari ^a   Øyan, Anne Margrete ^a   Puntervoll, Hanne ^a   Bø, Trond Hellem ^c   Stordrange, Laila ^c   Olsen, Sue ^a   Haukaas, Svein Andreas ^b,c   Hood, Leroy ^d   Jonassen, Inge ^c   Kalland, Karl Henning ^a   Akslen, Lars Andreas ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN SIM2 L; PROTEIN SIM2 S; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIM2 L GENE; SIM2 S GENE; TUMOR SUPPRESSOR GENE;

AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847396441     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1207     Document Type: Article

References (22)

1. Chen H, Chrast R, Rossier C, et al. Single-minded and Down syndrome? Nat Genet 1995;10:9-10.
2. Rahmani Z, Blouin JL, Creau-Goldberg N, et al. Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. Proc Natl Acad Sci U S A 1989;86:5958-62.
3. Chrast R, Scott HS, Chen H, et al. Cloning of two human homologs of the Drosophila single-minded gene SIM1 on chromosome 6q and SIM2 on 21q within the Down syndrome chromosomal region. Genome Res 1997;7:615-24.
4. Moffett P, Reece M, Pelletier J. The murine Sim-2 gene product inhibits transcription by active repression and functional interference. Mol Cell Biol 1997;17:4933-47.
5. Rachidi M, Lopes C, Charron G, et al. Spatial and temporal localization during embryonic and fetal human development of the transcription factor SIM2 in brain regions altered in Down syndrome. Int J Dev Neurosci 2005;23:475-84.
6. Goshu E, Jin H, Lovejoy J, Marion JF, Michaud JL, Fan CM. Sim2 contributes to neuroendocrine hormone gene expression in the anterior hypothalamus. Mol Endocrinol 2004;18:1251-62.
7. Shamblott MJ, Bugg EM, Lawler AM, Gearhart JD. Craniofacial abnormalities resulting from targeted disruption of the murine Sim2 gene. Dev Dyn 2002;224:373-80.
8. Goshu E, Jin H, Fasnacht R, Sepenski M, Michaud JL, Fan CM. Sim2 mutants have developmental defects not overlapping with those of Sim1 mutants. Mol Cell Biol 2002;22:4147-57.
9. Metz RP, Kwak HI, Gustafson T, Laffin B, Porter WW. Differential transcriptional regulation by mouse single-minded 2s. J Biol Chem 2006;281:10839-48.
10. Deyoung MP, Scheurle D, Damania H, Zylberberg C, Narayanan R. Down's syndrome-associated single minded gene as a novel tumor marker. Anticancer Res 2002;22:3149-57.
11. DeYoung MP, Tress M, Narayanan R. Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors. Proc Natl Acad Sci U S A 2003;100:4760-5.
12. DeYoung MP, Tress M, Narayanan R. Down's syndrome-associated Single Minded 2 gene as a pancreatic cancer drug therapy target. Cancer Lett 2003;200:25-31.
13. Halvorsen OJ, Oyan AM, Bo TH, et al. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol 2005;26:329-36.
14. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-9.
15. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
16. Gjertsen BT, Oyan AM, Marzolf B, et al. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. J Hematother Stem Cell Res 2002;11:469-81.
17. Oyan AM, Bo TH, Jonassen I, et al. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry B Clin Cytom 2005;64:18-27.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
19. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 2001;21:4071-6.
20. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. Urol Oncol 1997;3:59-66.
21. Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA, Akslen LA. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000;88:416-24.
22. Aleman MJ, Deyoung MP, Tress M, Keating P, Perry GW, Narayanan R. Inhibition of Single Minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells. Proc Natl Acad Sci U S A 2005;102:12765-70.